Febrile neutropenia anthracycline

In Phase I trials in the UK, HPMA copolymer doxombicin (PKl) given once every three weeks, had significantly reduced toxicity when compared to free doxombicin. The maximum tolerated dose, toxicity profile, and pharmacokinetics of PKl as an i.v. infusion every 3 weeks to patients with refractory or resistant cancers was determined. In the most recent report, 100 cycles were administered (range, 20-320 mg/m [free dmg equivalent]) to 36 patients (20 males and 16 females) with a mean age of 58.3 years (age range, 34-72 years). The maximum tolerated dose was 320 mg/m, and the dose-limiting toxicities were febrile neutropenia and mucositis. This maximum tolerated dose was a 4-5 fold increase over the usual clinical doses (60-80 mg/m ). No congestive cardiac failure was seen despite individual cumulative doses up to 1680 mg/m. Other anthracycline-like toxicities were attenuated. Pharmacokinefically, PKl had a distribution t(l/2) of 1.8 h and... 

Chan A, Chen C, Chiang J, Tan SH, Ng R. Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. Supportive Care Cancer 2012 20(7) 1525-32. 

---